Abstract: Disclosed are platforms, systems, media, and methods for enabling a clinical trial administrator to identify individuals potentially eligible for a clinical trial based at least in part on an individual molecular phenotype, review profiles of identified individuals, and make clinical trial enrollment offers to identified individuals. Also disclosed are platforms, systems, media, and methods for enabling a patient to review and accept or decline clinical trial enrollment offers and identify relevant individuals, clinical trials, and therapies based at least in part on an individual molecular phenotype.

Abstract: Disclosed herein are methods of diagnosing pancreatic cancer in a subject. Also provided are methods of monitoring the efficacy of a therapeutic treatment of pancreatic cancer as well as methods of determining the likelihood that a subject having pancreatic cancer will survive, and methods of determining the suitability of a subject having pancreatic cancer for surgical resection therapy.

Abstract: The present invention provides novel genes and proteins for diagnosing pancreatic cancer and/or a likelihood for survival e.g., following surgical resection, wherein the expression of the genes and proteins is up-regulated or down-regulated. The pancreatic cancer-associated genes and proteins of the invention are specifically exemplified by the genes and proteins set forth in Tables 3 to 25 and the Sequence Listing.